Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

As everyone knows, scratching at chronically itchy skin only makes the problem worse. A new device is claimed to help stop ...

Apple cider vinegar is fermented juice made from apples. It may be useful in blood sugar management, weight loss, and ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

An AI-enabled wearable sensor with vibratory feedback significantly reduces nocturnal scratching in atopic dermatitis, ...

Dryness between the fingers can be an uncomfortable and sometimes persistent issue but with the right care and preventive ...

Discover a study where findings revealed that using the new device significantly decreased both total and hourly scratch ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...